S&P upgrades Glenmark to 'BB' on expectation of conservative debt levels

The outlook is stable reflecting the view that Glenmark will maintain its financial policy such that its FFO-to-debt ratio will remain comfortably above 30%, S&P said

Standard and Poor’s (S&P) has upgraded long-term issuer rating on Glenmark Pharmaceuticals from “BB-” to “BB” on the expectation of conservative debt levels given limited upcoming capital investments and healthy free operating cash flow.

Its debt is likely to decline by about 25 per cent in FY22 (year ending March 31, 2022) given management's commitment to maintaining lower leverage following a recent equity raising at its subsidiary. This is expected to boost the company's ratio of funds from operations (FFO) to debt is expected at 35-40 per cent in FY22.

The outlook is stable reflecting the view that Glenmark will maintain its